LAUSR

RESULTS: In the cohort analyzed (n1⁄41,028,125), the prevalence of epilepsy was 0.44% (n1⁄44,528). Overall, 55% (n1⁄42,508) received any of these AEDs during pregnancy, the most common of which were lamotrigine (49.8%) and levetiracetam (42.5%). Compared to the non-epileptic control group, women on AEDs showed significant increases in the absolute risk of cesarean delivery (5.0%), preeclampsia (0.7%), severe preeclampsia/eclampsia (0.9%) and SMM (1.6%). AEDs with the highest increases in absolute risk were topiramate (6.7%) for cesarean delivery, lamotrigine for pre-eclampsia (1.1%), and lacosamide for severe preeclampsia/eclampsia (8.4%) and SMM (9.3%). Of the 2,508 women, 414 (16.5%) received more than one AED during pregnancy. Compared to women receiving a single AED, those who received multiple AEDs had higher absolute risks of all outcomes except postpartum hemorrhage (Table). CONCLUSION: Compared to non-epileptic women, women on newer generation AEDs demonstrated an increased absolute risk for cesarean delivery, preeclampsia, severe preeclampsia/eclampsia and severe maternal morbidity. Women receiving multiple medications demonstrated the highest increase in absolute risk for adverse outcomes, similar to findings in older AEDs, possibly also reflecting a more complicated and difficult disease state.